CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 68 enrolled
Drug / intervention
Fluoxetine +1 moredrug
Likely dose
Fluoxetine 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01545843
NCT01545843Phase 2Completed
CompareCT.gov

Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression

University of Michigan·interventional·Posted Mar 7, 2012·Updated Jan 30, 2023

In Brief

A Phase 2 clinical trial evaluating Sleep scheduling and Fluoxetine for Depression. Completed, enrolled 68 participants across 1 site.

Detailed Summary

The purpose of the study is to determine whether changing sleep patterns improves response to an antidepressant medication.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 7, 2012
Enrollment StartMar 1, 2009
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 14.3 years ago

Interventions

Sleep schedulingbehavioral

8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime

Fluoxetinedrug

20-40 mg fluoxetine daily for 8 weeks